Completed PHASE4 INTERVENTIONAL 2-arm NCT04695769

Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

The Role of Combined Ribavirin and Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment of Chronic Hepatitis C Non-responders; A Randomized Controlled Trial

Sponsor: Helwan University

Conditions Chronic Hepatitis C

Interventions Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin

Updated 4 times since 2021 Last updated: Aug 31, 2022 Started: Nov 21, 2020 Primary completion: Oct 21, 2021 Completion: Oct 21, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Chronic Hepatitis C, this trial is completed. The trial is conducted by Helwan University and has accumulated 4 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2022 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Feb 2021 — Sep 2022 [monthly]

Recruiting PHASE4

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Helwan University

Data source: Helwan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt